Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.90
Price+0.21%
$0.06
1Y
Price
Market Cap
$18.237b
Large
Price/Earnings 3y Avg5y Avg
15x
Premium
Premium
Financials Overview
Key metrics over the past few years+48.4%
EBITDA Margin+36.3%
Net Profit Margin+5.6%
Free Cash Flow MarginRevenue
$17.839b
-17.1%
1y CAGR+8.8%
3y CAGR+24.6%
5y CAGREarnings
$5.642b
-28.1%
1y CAGR+10.7%
3y CAGR+29.1%
5y CAGREPS
$8.79
-27.6%
1y CAGR+12.1%
3y CAGR+30.2%
5y CAGRBook Value
$5.302b
$6.464b
Assets$1.162b
Liabilities$148m
DebtDebt to Assets
2.3%
-
Debt to EBITDAFree Cash Flow
$4.912b
-35.2%
1y CAGR+22.6%
3y CAGR+37.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company